• Menu
  • Skip to right header navigation
  • Skip to main content

Before Header

Link Medical Research

CRO – Contract Research Organization

  • Home
  • Solutions
    • Early Development
    • Clinical Development
    • Post-Marketing
    • LINK Advantage
    • Market Access & RWE
    • Medical Device
    • Medical Experts
    • Medical Writing
    • Pharmacovigilance
    • Clinical Operations
    • Project Management
    • Quality Assurance
    • Regulatory Affairs
    • Marketing Compliance
    • Biometrics
    • Other Services
  • Therapeutic areas
  • About Us
    • Our Management
    • How We Work
    • Case Studies
    • Customer Testimonials
    • Our Memberships
  • News & Events
    • News
    • Events
    • Publications
    • Videos
  • Contact
  • Careers
    • Our Careers
    • Jobs
    • LINK Team Testimonials
  • Search
  • Home
  • Solutions
    • Early Development
    • Clinical Development
    • Post-Marketing
    • LINK Advantage
    • Market Access & RWE
    • Medical Device
    • Medical Experts
    • Medical Writing
    • Pharmacovigilance
    • Clinical Operations
    • Project Management
    • Quality Assurance
    • Regulatory Affairs
    • Marketing Compliance
    • Biometrics
    • Other Services
  • Therapeutic areas
  • About Us
    • Our Management
    • How We Work
    • Case Studies
    • Customer Testimonials
    • Our Memberships
  • News & Events
    • News
    • Events
    • Publications
    • Videos
  • Contact
  • Careers
    • Our Careers
    • Jobs
    • LINK Team Testimonials
  • Search

Top Content

Home / Another milestone reached for AlzeCure’s Phase II clinical trial in neuropathic pain with non-opioid ACD440

Top Content 2

Another milestone reached for AlzeCure’s Phase II clinical trial in neuropathic pain with non-opioid ACD440

Uppsala Sweden, June 22st
LINK Medical, the Northern European clinical research organization (CRO), and AlzeCure Pharma AB (publ) (FN STO: ALZCUR), announced today that the first patient has been enrolled in the phase II clinical trial for neuropathic pain treated with the non-opioid ACD440.

Alzecure is a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain. This is a unique trial leading a non-opioid drug candidate in the painless platform which is being developed for peripheral neuropathic pain.

The regulatory authorities recently approved for the study to start. The Phase II clinical trial is a double-blind, placebo-controlled, randomized cross-over study evaluating the efficacy, safety, and pharmacokinetics of AlzeCure’s leading drug candidate in pain, ACD440. Results from the study are expected in mid-2023.

ACD440 is a TRPV1 antagonist and first-in-class local treatment for patients with peripheral neuropathic pain. The discovery of TRPV1, which is the basis for the project, was awarded the Nobel Prize in Physiology or Medicine in 2021. ACD440, which is applied as a gel, is the company’s leading drug candidate in the Painless platform and Alzecure conducted a positive phase Ib study in 2021.

The medical need in neuropathic pain is great, not least to find alternatives to opioids. The market for neuropathic pain is the single largest market segment in pain treatment, with annual sales of over USD 11 billion. Up to 80% of patients do not get a satisfactory effect with their current treatments.

“We are very pleased to have been able to initiate this important study with ACD440 according to plan,” said Märta Segerdahl, project manager and CMO at AlzeCure Pharma. “Neuropathic pain is an area of great medical need, and we believe that ACD440 could significantly improve the quality of life for patients suffering from neuropathic pain.”

“This is a big step for both the project and the company, as we are now a phase II company. With the previous positive results from the phase Ib study, we look forward to the reading of this study, which can generate even greater interest in our licensing,” said Martin Jönsson, CEO of AlzeCure Pharma.

 “We are delighted to work with AlzeCure Pharma and be their trusted strategic partner. The present groundbreaking study has the obvious potential to improve the treatment for neuropathic pain through a novel mechanism of action. We are also happy to introduce the decentralized approach into this project which will make the process easier, faster, and most efficient for all stakeholders.”  said Ola Gudmundsen, CEO of LINK Medical

About Neuropathic pain
Neuropathic pain affects approximately 7–8 percent of the total adult population. Some patients, with indications such as diabetes and HIV, are affected to a greater extent, where approximately 25 and 35 percent respectively of the patients experience neuropathic pain.

Peripheral neuropathic pain is the result of various types of damage to the nerve fibers, such as toxic, traumatic, or nerve compression injuries as well as metabolic and infectious diseases… Common symptoms are painful tingling that can be described as “pins and needles”, choking or burning pain, as well as the feeling of getting an electric shock. Patients may also experience allodynia (pain caused by a stimulus that usually does not cause pain) or hyperalgesia (increased pain from a stimulus that normally provokes pain).

The market for neuropathic pain is characterized by a major medical need in all indications and in all major markets, where only about 50 percent of patients respond to existing treatment. Due to the risk of abuse, overdose, and secondary injuries, people are now trying to avoid opiates as first-line treatment for pain. Despite these treatment problems, these drugs are still used frequently, and therefore the need for new treatments that are not opiates is very great.

The patient population will grow, among other things, due to an aging population and increased number of long-term cancer survivors, and the increasing prevalence of type-2 diabetes.

The global market for neuropathic pain was valued at $5 billion in 2015 and is expected to grow to $8 billion by 2024. 

 

About LINK Medical 

LINK Medical is a full-service contract research organization (CRO) providing product development services for the pharmaceutical and medical device industries across Northern Europe. We offer a well-integrated local presence in all Nordic countries, UK and Germany. Reaching from early phase development to post-marketing, we have over 200 employees providing expert guidance across every aspect of a project – all from ONE source. Our promise is to improve and accelerate your product development through transformative methods, active communication, and optimal solutions. As a strategic partner, we provide expert competence and technology to enable evidence-based decision-making that supports the delivery of superior clinical outcomes.
www.LINKMedical.eu | info@LINKMedical.eu

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative small molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease and comprises two drug candidates. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets other types of severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase and is continually working on business development to find suitable solutions for license agreements with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se

For more information, please contact

LINK Medical
Ola Gudmundsen, CEO
Tel: 4792462200
Ola.Gudmundsen@LINKMedical.eu

Editorial contact:
Claudia Wennberg, Marketing and Brand Manager
+46708244398
Claudia.Wennberg@LINKMedical.eu

AlzeCure Pharma
Martin Jönsson, CEO
Tel: +46 707 86 94 43
Martin.Jonsson@alzecurepharma.com

Previous Post: « Pharmaceutical Social Media – the dos and don’ts from a Medical Compliance perspective
Next Post: Senior Clinical Research Associate CRO – Contract Research Organization»

Site Footer

Don't miss out on the latest updates

Be the first to hear our breaking news at LINK Medical

  • Home
  • Solutions
  • Therapeutic areas
  • About Us
  • News & Events
  • Contact
  • Careers
  • Search

© 2023 LINK Medical Research
Privacy Policy

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Read More
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_142237341_11 minuteSet by Google to distinguish users.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
nQ_cookieId1 yearAlbacross sets this cookie to help identify companies for better lead generation and more effective ad targeting.
nQ_userVisitId30 minutesNo description available.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
CookieDurationDescription
VISITOR_INFO1_LIVE5 months 27 daysA cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSCsessionYSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devicesneverYouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-idneverYouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
SAVE & ACCEPT
Powered by CookieYes Logo